Overview: Anti-A Titer IgG TestIntroduction: The Anti-A Titer IgG Test measures IgG antibodies to blood group A antigens to assess blood transfusion compatibility or immune responses. Aligned with 2023 AABB guidelines, it uses an immunoassay for high sensitivity, aiding in blood typing screening. This test is critical for ensuring safe transfusions, managing hemolytic disease, and improving outcomes in immunology for patients requiring blood products or with immune-mediated conditions.
Other Names: Anti-A IgG Assay, Blood Group A IgG Titer Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Blood group antibody testing began in the 1940s with agglutination methods. IgG-specific assays emerged in the 1980s, and by the 2000s, immunoassays improved precision for transfusion compatibility.
Purpose: Assesses blood transfusion compatibility, guides transfusion planning, and monitors immune responses in patients at risk of blood group incompatibility.
Test Parameters: 1. Anti A Titre IgG
Pretest Condition: No fasting required. Collect serum or saliva at any time. Report transfusion history, pregnancy, or symptoms of hemolysis, and list medications like immunosuppressants.
Specimen: 2-5 mL serum (serum separator tube, SST) or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours to maintain sample integrity.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document transfusion history, pregnancy, hemolytic symptoms, or family history of blood group incompatibilities. Include current medications, especially immunosuppressants or blood products.
Consent: Written consent required, detailing the tests purpose, implications for transfusion safety, and potential need for further blood typing or treatment.
Procedural Considerations: Uses an immunoassay (e.g., enzyme-linked immunosorbent assay) to measure Anti-A IgG titers. Results are available in 1-2 days, enabling rapid clinical decisions. Performed in laboratories with strict quality controls.
Factors Affecting Result Accuracy: Recent transfusions or immunosuppressive drugs may alter IgG levels. Hemolysis or improper storage can degrade samples. Cross-reactivity with other antibodies may affect specificity.
Clinical Significance: Elevated Anti-A IgG titers indicate incompatibility, prompting careful blood matching or treatment for hemolytic disease. Normal levels support safe transfusion planning.
Specialist Consultation: Consult a transfusion medicine specialist or hematologist for result interpretation. An obstetrician referral is advised for pregnancy-related cases.
Additional Supporting Tests: ABO typing, Coombs test, or Anti-B IgG test to confirm compatibility or assess hemolytic risk.
Test Limitations: False positives may occur with autoimmune conditions or recent transfusions. Low-level antibodies may require confirmatory testing.
References: AABB Transfusion Guidelines, 2023; Transfusion Medicine, Hillyer CD, 2022.
